FDA Issues Complete Response Letter For Sanofi's Tolebrutinib In NrSPMS Review

The FDA has issued a complete response letter for Sanofi's new drug application for tolebrutinib to treat non‑relapsing secondary progressive multiple sclerosis, prompting Sanofi to continue engagement with regulators and submit an expanded access protocol. Sanofi earlier signaled the U.S. review would extend beyond the Dec. 28, 2025 target action date and expects further FDA guidance by end‑Q1 2026; the drug has provisional UAE approval (July 2025) and is under review in the EU and other jurisdictions. The company is conducting an IFRS (IAS 36) impairment test on the intangible asset tied to tolebrutinib, to be disclosed with Q4 and FY‑2025 results in January 2026, and said the outcome will not affect business net income, business EPS or its 2025 financial guidance. Shares closed at $48.32 on Dec. 23, 2025, up 0.6% on the day and flat in after‑hours trading.

Analysis

Market structure: The CRL materially reduces Sanofi's near-term optionality in the nrSPMS segment and hands tactical advantage to established MS incumbents (e.g., Roche/RHHBY, Novartis/NVS) who can defend pricing and retain access to neurologists; expect downward pressure on SNY market share capture worth potentially hundreds of millions to >$1bn in annual peak sales if approval is delayed >12 months. Biotech peers with BTK programs face mixed signalling—regulation tightening raises development risk premiums, while successful remedial steps by Sanofi would re-open the field.

Risk assessment: Tail risks include a protracted FDA-requested Phase 3/labeling study that forces an impairment >$1bn and an equity sell-off >20–30%; immediate risk is elevated IV (options) and a 5–15% move within days, short-term (weeks–months) hinges on the Jan 2026 impairment disclosure and FDA guidance by end-Q1 2026, long-term (12–24 months) depends on final approval pathway. Hidden dependency: valuation damage is binary to FDA path clarity — expanded access mitigates revenue loss but complicates labeling and safety perception.

Trade implications: Tactical trades should favor defined-risk bearish exposure to SNY and relative-long exposure to large-cap diversified pharma (NVS, PFE) for 3–9 months. Use put-spreads and pair-trades rather than outright shorts to limit borrow/volatility; re-evaluate after Jan 2026 Q4 results and any FDA feedback expected by end-Q1 2026.

Contrarian angles: Consensus may overprice permanent loss — management kept 2025 guidance unchanged and pursued expanded access, signalling internal probability of remediation >50%; history shows many CRLs cause 20–40% knee-jerk drops but recover within 6–12 months if fixes are procedural. If SNY falls >20% and impairment is <$500m, asymmetric upside from long-dated calls is attractive; conversely, if FDA asks for new trials, downside can be severe and prolonged.

Key Decisions for Investors

• Establish a defined-risk bearish position: allocate 1.5–2.0% of NAV to a 3-month SNY put spread (buy SNY Mar-2026 $44 put / sell Mar-2026 $38 put) to capture a 10–25% downside with capped premium; close if SNY rises +10% from entry or if FDA provides a clear approval pathway.
• Implement a pair trade for 3–9 months: short SNY equity equal to 1.0–1.5% of NAV and go long NVS (Novartis) 1.0% of NAV to play MS market share shift and defensive pharma resilience; rebalance after Jan 2026 Q4 results or after FDA guidance by end-Q1 2026.
• Event-driven asymmetric long: if SNY declines >20% (below ~$38), allocate 0.5% NAV to long-dated (12+ month) SNY calls (e.g., Jan-2027 $55 calls) to capture upside if the CRL is remediated with limited capital at risk.
• Reallocate 3–5% of biotech exposure toward large-cap, cash-generative pharma (NVS, PFE) over the next 30 days to reduce binary regulatory beta; avoid adding to SNY equity until the impairment test disclosed with Q4 results in Jan 2026 and FDA comments by end-Q1 2026 are parsed.